October 2022
180 articles-
Oct 31 · 07:14Biotechnology Daily
Scandion posts phase 2 trial flop just one month after the departure of 2 top execs
-
Oct 31 · 07:11Biotechnology Daily
Don't junk DNA as study shows new role in brain disease
-
Oct 31 · 07:10Biotechnology Daily
Disruptive gene technology is here—and society seems willing to pay for it
-
Oct 31 · 07:08Biotechnology Daily
GE Healthcare nabs FDA clearance for deep-learning MRI imaging software
-
Oct 31 · 07:07Bio Business News
Solid Bio hopes to fortify itself after fusing with AavantiBio, but not before axing its lead asset
-
Oct 31 · 07:05Bio Business News
New pediatric data shoot Rocket's gene therapy toward phase 2, leaving behind FDA concerns
-
Oct 31 · 06:59Bio Business News
Gene editing execs reflect on promises and challenges as CRISPR celebrates 10-year anniversary
-
Oct 31 · 06:37Bio Business News
Illumina pitches $200 genomes with new line of DNA sequencers
-
Oct 28 · 05:33Biotechnology Daily
Invisalign maker rolls out AI app for home-directed treatment
-
Oct 28 · 05:32Biotechnology Daily
Leveraging machine learning to hone precision meds targeting cancer backup genes
-
Oct 28 · 05:31Biotechnology Daily
J&J Vision sees new FDA green light for contact lenses to combat nearsightedness
-
Oct 28 · 05:29Biotechnology Daily
Galecto links blood cancer prospect to reduced fibrosis in early data drop
-
Oct 28 · 05:27Bio Business News
Good Idera: Pharma buys rare-disease-focused Aceragen in all-stock deal to keep money flowing
-
Oct 28 · 05:26Bio Business News
Aligos demands jury trial to settle Janssen theft allegations, files fraud counterclaims
-
Oct 28 · 05:25Bio Business News
Biohaven's Nurtec-less pipeline takes another gut punch, fails ALS trial
-
Oct 28 · 05:24Bio Business News
Novo enters NLRP3 arena, paying Ventus $70M for NASH hopeful
-
Oct 28 · 03:47Market Watch
U.S. jobless claims tick up in latest week
-
Oct 27 · 05:30Biotechnology Daily
With cash dwindling, Axcella shares look at blinded NASH data
-
Oct 27 · 05:29Biotechnology Daily
FDA clears Medtronic's powder-to-gel bloodstopping spray for upper GI bleeds
-
Oct 27 · 05:27Biotechnology Daily
TCR2's cell therapy racks up 22% response rate in heavily pretreated solid tumor patients
-
Oct 27 · 05:26Biotechnology Daily
Eisai and Biogen's phase 3 Alzheimer's win puts amyloid back in the driver's seat, for now
-
Oct 27 · 05:24Bio Business News
ConcertAI, LSU Health New Orleans team up to tackle clinical trial diversity
-
Oct 27 · 05:22Bio Business News
Pfizer, AstraZeneca, Merck KGaA-backed Israeli AI incubator launches first biopharma startup
-
Oct 27 · 05:21Bio Business News
Out of Context: CEO says now not the time to build a 'big independent biotech'